How to Help Your Patients Find Dihydroergotamine in Stock: A Provider's Guide

You've prescribed Dihydroergotamine for your patient's migraines. It's the right clinical choice. But your patient calls back the next day — the pharmacy doesn't have it. They've tried three pharmacies. Nobody has stock. Now what?

This scenario is playing out daily across the country as the Dihydroergotamine shortage continues into 2026. As a provider, you can play a pivotal role in helping patients navigate the access challenge. This guide offers practical steps your practice can take today.

Current Availability of Dihydroergotamine

As of early 2026, the availability landscape for Dihydroergotamine breaks down as follows:

• Injectable (D.H.E. 45 and generics) — severely limited. Listed as "Currently in Shortage" on the FDA database. Perrigo has discontinued its generic. Hospital and retail pharmacy supply is inconsistent.
• Nasal spray (generic Migranal) — intermittently available. More likely to be in stock than the injectable, but still subject to supply disruptions.
• Trudhesa (MAP nasal spray) — generally available through specialty pharmacy networks with a dedicated supply chain.
• Brekiya (subcutaneous autoinjector) — FDA approved in 2025. Available through specialty pharmacies. Uses a separate supply chain from the older formulations.

Why Patients Can't Find Dihydroergotamine

Understanding the root causes helps frame conversations with patients and supports clinical decision-making:

• Manufacturer consolidation — the number of companies producing DHE has declined, with Perrigo's exit being the most impactful
• Ergot alkaloid production complexity — the natural compound derivation process is slow and difficult to scale
• Distribution fragmentation — chain pharmacies and hospital systems often use single-source distribution, meaning when their supplier is out, they're out
• Patient awareness gap — many patients don't know that other formulations exist or that specialty pharmacies may have stock

What Providers Can Do: 5 Practical Steps

Step 1: Prescribe with Formulation Flexibility

When clinically appropriate, consider writing prescriptions that give the pharmacy flexibility. If your patient can use either the nasal spray or the injectable, writing for both formulations (as separate prescriptions) gives the pharmacy two avenues to fill. Discuss Trudhesa and Brekiya as named alternatives if generic options are unavailable.

Step 2: Direct Patients to Real-Time Availability Tools

Rather than having patients call pharmacies blindly, point them to Medfinder for Providers. This tool shows real-time pharmacy stock levels, so patients can identify which nearby pharmacies currently have Dihydroergotamine before making calls or visits.

Consider adding the Medfinder link to your after-visit summary or patient portal messages for DHE prescriptions.

Step 3: Build Relationships with Specialty Pharmacies

Specialty pharmacies that distribute Trudhesa and Brekiya often have more reliable DHE access than retail pharmacies. Establishing a relationship with one or two specialty pharmacies in your area (or the manufacturers' preferred pharmacies) can create a more consistent pathway for your patients.

Trudhesa and Brekiya both offer HCP support portals that can help with enrollment, coverage verification, and patient onboarding.

Step 4: Proactively Address Cost Barriers

Cost is a major reason patients abandon DHE prescriptions — particularly for brand-name products. Help patients access savings programs before they face sticker shock at the pharmacy counter:

• Trudhesa Direct Savings — eligible commercially insured patients may pay as little as $0 per prescription
• Brekiya Copay Program — eligible commercially insured patients may pay as little as $40 per carton
• Discount cards — GoodRx and SingleCare can reduce generic DHE prices to ~$262–$286

Step 5: Document the Shortage for Insurance Appeals

When switching patients to brand-name formulations or alternative agents due to the shortage, document the clinical rationale and the shortage status in your notes. This documentation is critical for supporting prior authorization requests and insurance appeals, particularly when payers require step therapy through a product that is unavailable.

Include reference to the FDA Drug Shortage Database listing and any pharmacy documentation confirming unavailability.

Alternatives to Consider

When DHE is truly unavailable in any formulation, consider these alternative acute migraine agents:

• Sumatriptan (SC injection or nasal spray) — widely available, affordable generic. Note: 24-hour separation from DHE required. Higher migraine recurrence rate than DHE.
• Ergotamine/Caffeine (Cafergot) — same ergot class. Oral and rectal formulations. Higher side effect profile than DHE. Same cardiovascular contraindications.
• Lasmiditan (Reyvow) — 5-HT1F agonist, no vasoconstrictive effect. Suitable for patients with cardiovascular contraindications. Schedule V; causes sedation.
• Ubrogepant (Ubrelvy) — oral CGRP antagonist. No vasoconstriction. Generally well-tolerated. Interacts with strong CYP3A4 inhibitors.

Workflow Tips for Managing the Shortage

• Flag DHE patients in your EHR — create a care management list so you can proactively reach out if supply changes
• Pre-authorize alternatives — submit PAs for backup medications before patients run out of DHE, so coverage is ready when needed
• Standardize patient education — create a handout or template message explaining the shortage, alternative formulations, and resources like Medfinder
• Monitor ASHP and FDA updates — sign up for email alerts from both databases to stay ahead of supply changes

Final Thoughts

The Dihydroergotamine shortage puts an extra burden on already-busy providers. But with the right tools, proactive planning, and awareness of all available formulations, you can significantly improve your patients' experience — even when supply is tight.

Start by checking current availability through Medfinder for Providers and sharing the resource with your patients and care team.

Related: Dihydroergotamine Shortage: What Providers and Prescribers Need to Know in 2026